Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
PSNL Personalis Inc
CORR CorEnergy Infrastructure Trust Inc
SBRA Sabra Health Care REIT Inc
ZI ZoomInfo Technologies Inc
ATNI ATN International Inc
BAC Bank of America Corp
RACE Ferrari NV
PTICW PropTech Investment II Equity Warrant Exp 8th Dec 2027 *W EXP 12/08/2027
TKPHF Takeda Pharmaceutical Co Ltd
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Price
Delayed
$625.62
Day's Change
14.40 (2.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
628.05
Day's Low
612.40
Volume
(Light)

Today's volume of 292,954 shares is on pace to be much lighter than REGN's 10-day average volume of 752,451 shares.

292,954

JPMorgan Chase stock up 1.4% premarket ahead of Q4 results

6:42 am ET January 14, 2022 (MarketWatch)
Print
	

(END) Dow Jones Newswires

January 14, 2022 06:42 ET (11:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.